Riluzol PMCS (Riluzole 50 mg)
Generic glutamate release inhibitor for the treatment of amyotrophic lateral sclerosis (ALS)
Quick Facts About Riluzol PMCS
Key Takeaways About Riluzol PMCS
- Generic riluzole: Riluzol PMCS is a bioequivalent generic version of the original reference product Rilutek, with the same active ingredient (riluzole 50 mg) and identical therapeutic effect
- First-line ALS treatment: Riluzole is one of the few disease-modifying treatments for ALS and is recommended by international guidelines including EMA, FDA, NICE, and AAN
- Extends survival: Clinical trials have shown riluzole extends survival by approximately 2–3 months and may delay the need for tracheostomy or mechanical ventilation
- Liver monitoring is essential: Regular blood tests to check liver function (transaminases) are required, especially during the first year of treatment
- Simple twice-daily dosing: One 50 mg tablet taken every 12 hours, at the same times each day, swallowed whole with water
What Is Riluzol PMCS and What Is It Used For?
Riluzol PMCS is a generic prescription medicine used to treat amyotrophic lateral sclerosis (ALS), also known as motor neuron disease or Lou Gehrig's disease. It contains 50 mg of riluzole, a glutamate release inhibitor that works by reducing excitotoxic damage to motor neurons in the brain and spinal cord.
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that affects the motor neurons – the nerve cells responsible for sending signals from the brain and spinal cord to the muscles. As these nerve cells deteriorate and die, patients gradually lose the ability to move, speak, swallow, and eventually breathe. ALS affects approximately 2–5 per 100,000 people worldwide, with most cases occurring between the ages of 40 and 70. Treatment options remain limited, making riluzole one of the most important medicines for this condition.
The active substance in Riluzol PMCS is riluzole, a benzothiazole compound that acts on the central nervous system. Riluzole was the first drug approved specifically for ALS, receiving initial authorization from the U.S. Food and Drug Administration (FDA) in 1995 and subsequently from the European Medicines Agency (EMA) in 1996. As patent protection on the reference product Rilutek has expired, several generic versions – including Riluzol PMCS – have entered the market, providing wider access to this essential medicine at lower cost.
The primary mechanism of action involves inhibiting the release of glutamate, an excitatory neurotransmitter that plays a central role in normal brain function. In ALS, excessive glutamate activity is believed to cause excitotoxic damage to motor neurons. By blocking glutamate release from presynaptic nerve terminals, interfering with voltage-dependent sodium channels, and modulating intracellular signaling pathways following glutamate receptor binding, riluzole helps protect motor neurons from progressive destruction. Riluzol PMCS delivers the same active substance and therefore the same neuroprotective effect as the reference product.
It is important to understand that Riluzol PMCS does not cure ALS and does not reverse damage that has already occurred to motor neurons. However, the two pivotal randomized controlled trials published in the 1990s demonstrated that riluzole can extend survival by approximately 2–3 months and delay the need for mechanical ventilation. Real-world evidence from subsequent registry studies suggests that the benefit may be even greater in clinical practice, particularly when treatment is initiated early in the disease course. This makes timely diagnosis and prompt initiation of therapy a priority in ALS management.
A generic medicine is a pharmaceutical product that contains the same active ingredient, in the same strength and dosage form, as an originally patented brand-name product. Before a generic can be approved, the manufacturer must demonstrate bioequivalence – meaning the generic delivers the active substance into the bloodstream at a comparable rate and extent as the reference product. Generic medicines undergo the same rigorous quality standards as the original product and are reviewed by regulatory authorities such as the EMA and FDA. Riluzol PMCS is such a generic, bioequivalent to Rilutek, and provides the same clinical efficacy and safety profile.
Glutamate is the most abundant excitatory neurotransmitter in the central nervous system and plays essential roles in learning, memory, and motor control. However, when glutamate accumulates to excessive levels – as appears to occur in ALS – it overstimulates neurons, leading to a cascade of calcium-mediated events that ultimately causes cell death. This process, known as excitotoxicity, is considered one of the key pathological mechanisms in ALS. By reducing glutamate release, Riluzol PMCS helps mitigate this destructive process and slows motor neuron loss.
What Should You Know Before Taking Riluzol PMCS?
Before starting Riluzol PMCS, your doctor must evaluate your liver function, current medications, and overall health status. Riluzole is contraindicated in patients with liver disease or elevated transaminases, during pregnancy and breastfeeding, and in those with known hypersensitivity to riluzole or any excipient.
Taking any medication – especially one that requires long-term use – calls for careful consideration of potential risks and benefits. Because riluzole is metabolized primarily by the liver and can cause hepatotoxicity, a thorough medical evaluation is necessary before starting treatment. Your prescribing physician will consider your complete medical history, current medications, and laboratory results to determine whether Riluzol PMCS is appropriate for you. Baseline liver function tests are mandatory before the first dose.
It is also important to discuss any other medical conditions, allergies, or lifestyle factors that could influence treatment. For example, smoking can induce the liver enzyme CYP1A2 that metabolizes riluzole, potentially reducing its effectiveness. Your doctor may ask about your diet, alcohol use, and any herbal supplements you take, as these can also affect how your body processes the medication.
Contraindications
You should not take Riluzol PMCS if any of the following apply to you:
- Hypersensitivity: If you have ever had an allergic or hypersensitivity reaction to riluzole or to any of the excipients listed in the composition section, you must not take this medicine
- Liver disease: If you have an existing liver condition (such as hepatitis or cirrhosis) or if pre-treatment blood tests show elevated levels of liver enzymes (transaminases more than 3 times the upper limit of normal), riluzole should not be used, as it can worsen liver function
- Pregnancy: Riluzole is contraindicated during pregnancy due to insufficient safety data and findings of reproductive toxicity in animal studies
- Breastfeeding: It is not known whether riluzole is excreted in human milk, and breastfeeding is contraindicated during treatment due to potential risks to the nursing infant
Warnings and Precautions
Speak with your doctor before taking Riluzol PMCS if any of the following situations apply to you:
- Signs of liver problems: If you notice yellowing of the skin or whites of the eyes (jaundice), widespread itching, unexplained nausea, vomiting, or dark urine, contact your doctor immediately. These can be signs of liver inflammation (hepatitis). Regular blood tests are essential to monitor liver function throughout treatment
- Kidney impairment: If your kidneys are not working properly, inform your doctor. Although riluzole is primarily cleared via the liver, renal impairment may require closer monitoring
- Unexplained fever or infection: Report any fever promptly. Riluzole can reduce the number of white blood cells (neutropenia), which increases infection risk. A blood test may be needed to check your white blood cell count
- Respiratory symptoms: Tell your doctor if you develop a dry cough or worsening shortness of breath. Although rare, riluzole can cause interstitial lung disease, which requires prompt evaluation
- Smoking status: If you smoke, inform your doctor. Cigarette smoke induces the enzyme CYP1A2 and may lower riluzole blood levels
Your doctor should check your liver enzymes (ALT/AST) before starting treatment, monthly for the first 3 months, every 3 months for the rest of the first year, and periodically thereafter. If transaminase levels rise above 5 times the upper limit of normal, treatment should be stopped. Tell your doctor immediately if you develop any signs of liver problems such as jaundice, persistent nausea, vomiting, dark urine, or unusual tiredness.
Pregnancy and Breastfeeding
You must not take Riluzol PMCS if you are pregnant, think you may be pregnant, or are planning to become pregnant. There is insufficient data on the use of riluzole in pregnant women, and animal studies have shown potential reproductive toxicity including embryo-fetal effects. If you are a woman of childbearing potential, discuss appropriate contraception with your doctor before starting treatment. Effective contraception should be maintained throughout the treatment period.
It is not known whether riluzole is excreted in human breast milk. Given the potential risks to the nursing infant, breastfeeding should be discontinued before starting Riluzol PMCS therapy. If you are planning a pregnancy or discover that you are pregnant during treatment, contact your doctor immediately to discuss the best course of action. Abruptly stopping riluzole has not been associated with withdrawal effects, but any treatment changes should be made under medical supervision.
Children and Adolescents
Riluzol PMCS is not recommended for patients under 18 years of age. There is insufficient clinical data on the safety and efficacy of riluzole in children and adolescents. ALS is exceedingly rare in this age group, and if a motor neuron disease is suspected in a young patient, alternative diagnoses (such as juvenile ALS or hereditary spastic paraplegia) should be thoroughly considered. Any use in minors should only occur under specialist supervision in a research or specialized clinical setting.
Driving and Operating Machinery
You may drive and use machinery while taking Riluzol PMCS, provided you do not experience dizziness or drowsiness. These are known side effects of riluzole, and if they occur, you should avoid driving or operating dangerous machinery until the symptoms resolve. Additionally, ALS itself can impair motor function, reaction time, and muscle strength, which may progressively affect your ability to drive safely. Discuss with your neurologist how your condition and medication may affect driving ability, and check local regulations regarding driving with a neurological diagnosis.
Elderly and Patients with Other Conditions
No dose adjustment is required for elderly patients, but because older individuals are more likely to have reduced hepatic or renal function and to be taking multiple medications, closer monitoring may be prudent. Patients with pre-existing cardiovascular conditions should inform their doctor, as riluzole can occasionally cause tachycardia (increased heart rate). If you are taking other hepatotoxic medications, have a history of alcohol abuse, or have chronic viral hepatitis, the risk of liver-related side effects is increased.
How Does Riluzol PMCS Interact with Other Drugs?
Riluzole is primarily metabolized by the liver enzyme CYP1A2. Drugs that inhibit CYP1A2 (such as fluvoxamine and ciprofloxacin) can significantly increase riluzole blood levels, while CYP1A2 inducers (such as rifampicin, omeprazole, and cigarette smoking) can decrease its effectiveness. Always inform your doctor about all medicines you are taking.
Drug interactions are an important consideration with any long-term medication. Riluzole is extensively metabolized in the liver, primarily by the cytochrome P450 enzyme CYP1A2, with minor contributions from CYP3A4, CYP2C9, and CYP2D6. Because of this metabolic pathway, several classes of drugs can affect riluzole plasma concentrations, potentially increasing the risk of side effects (particularly hepatotoxicity) or reducing the drug's effectiveness.
It is essential to tell your doctor or pharmacist about all medicines you are currently taking, have recently taken, or might take. This includes prescription drugs, over-the-counter medications, herbal supplements, and vitamins. St. John's wort, echinacea, and certain dietary supplements can affect liver enzymes and should be disclosed. Your doctor can then assess whether any adjustments to your treatment plan are needed before starting Riluzol PMCS or if another medication is added.
| Interacting Drug | Effect | Severity | Recommendation |
|---|---|---|---|
| Fluvoxamine (CYP1A2 inhibitor) | Increases riluzole levels up to 5-fold | Major | Avoid combination; use an alternative antidepressant |
| Ciprofloxacin (CYP1A2 inhibitor) | Significantly increases riluzole levels | Major | Use alternative antibiotic if possible |
| Enoxacin, ticlopidine (CYP1A2 inhibitors) | Can increase riluzole exposure | Major | Avoid if possible; monitor liver function closely |
| Rifampicin (CYP1A2 inducer) | Decreases riluzole levels; may reduce efficacy | Moderate | Monitor closely; consider alternative antibiotic |
| Omeprazole (CYP1A2 inducer) | May decrease riluzole levels | Moderate | Consider alternative proton pump inhibitor |
| Theophylline (CYP1A2 substrate) | Competitive metabolism; may alter levels of both drugs | Moderate | Monitor theophylline levels closely |
| Caffeine (CYP1A2 substrate) | Competitive metabolism; minor theoretical interaction | Minor | Normal caffeine intake acceptable; avoid excessive consumption |
| Hepatotoxic drugs (e.g. methotrexate, isoniazid, high-dose paracetamol) | Increased risk of liver damage | Major | Avoid if possible; increase liver monitoring frequency |
| Cigarette smoking | Induces CYP1A2; may decrease riluzole levels | Moderate | Inform doctor of smoking status; consider smoking cessation support |
Major Interactions
The most clinically significant interaction is with fluvoxamine, a selective serotonin reuptake inhibitor (SSRI) used as an antidepressant and a potent CYP1A2 inhibitor. Co-administration with riluzole can increase plasma concentrations by up to 5-fold, dramatically increasing the risk of hepatotoxicity and other adverse effects. This combination should be avoided entirely; alternative antidepressants such as sertraline, citalopram, or mirtazapine may be considered after discussion with your prescribing physician. Similarly, ciprofloxacin, a commonly prescribed fluoroquinolone antibiotic, is a strong CYP1A2 inhibitor and can substantially raise riluzole levels.
Other potent CYP1A2 inhibitors to be aware of include enoxacin, ticlopidine, methoxsalen, and some herbal preparations. Concomitant use of other hepatotoxic medications – such as certain antifungals (ketoconazole, itraconazole), anticonvulsants (valproate), tuberculosis drugs (isoniazid), or chronic high-dose acetaminophen (paracetamol) – can compound the liver risks associated with riluzole. If such combinations are unavoidable, more frequent liver function monitoring is required, and treatment should be discontinued promptly if significant enzyme elevations develop.
Minor Interactions
Mild CYP1A2 inducers and inhibitors may have modest effects on riluzole blood levels that are generally not clinically significant but should still be considered. Caffeine is a CYP1A2 substrate; while normal dietary caffeine intake (1–3 cups of coffee per day) is unlikely to cause problems, very high caffeine consumption could theoretically compete with riluzole metabolism. Charcoal-grilled foods contain polycyclic aromatic hydrocarbons that induce CYP1A2 and may slightly reduce riluzole levels if consumed regularly in very large quantities, though this is rarely clinically relevant.
Cruciferous vegetables (broccoli, Brussels sprouts) also induce CYP1A2 mildly, but normal dietary intake is safe. Always discuss dietary concerns with your healthcare team if you are worried about interactions.
What Is the Correct Dosage of Riluzol PMCS?
The recommended dose of Riluzol PMCS is one 50 mg tablet twice daily (total 100 mg/day), taken every 12 hours at the same times each day, such as morning and evening. Swallow the tablets whole with water, with or without food. Do not adjust the dose without consulting your doctor.
Always take Riluzol PMCS exactly as your doctor has prescribed. If you are unsure about any aspect of your dosing, consult your doctor or pharmacist. The standard dosing regimen is simple and consistent: one 50 mg tablet in the morning and one in the evening, ideally spaced approximately 12 hours apart. This regimen has been optimized through clinical research to provide the best balance of efficacy and tolerability.
Consistency in timing is important to maintain stable blood levels of riluzole throughout the day. Taking doses at irregular intervals can lead to peaks and troughs in drug concentration, which may affect both efficacy and side effect profile. Many patients find that setting a daily alarm or linking their doses to routine activities (such as breakfast and bedtime) helps maintain adherence. Riluzol PMCS tablets can be taken with or without food; however, because a high-fat meal can slightly reduce absorption, consistent timing with respect to meals is recommended.
Adults
Standard Adult Dosage
50 mg (one tablet) twice daily, taken approximately every 12 hours. The total daily dose is 100 mg. Swallow the tablet whole with a glass of water. Riluzol PMCS can be taken with or without food, though taking it at the same times each day helps ensure consistent drug levels. Do not crush, chew, or break the tablets unless specifically advised by your doctor or pharmacist.
Clinical trials evaluated various doses of riluzole, ranging from 50 mg to 200 mg daily. The 100 mg daily dose (50 mg twice daily) was established as the optimal balance between efficacy and tolerability. Higher doses did not provide additional survival benefit but were associated with a significantly increased risk of adverse effects, particularly liver toxicity and nausea. Therefore, the standard 100 mg/day dose should not be exceeded under any circumstances.
Children
Pediatric Use
Not recommended. Riluzol PMCS is not approved for use in patients under 18 years of age. Insufficient clinical data exist regarding the safety and efficacy of riluzole in pediatric populations. ALS is exceedingly rare in children, and alternative diagnoses should be carefully considered. Use in this population should only occur under exceptional circumstances with specialist supervision in a research or expert center setting.
Elderly
Elderly Patients (65+ years)
No dose adjustment is generally required for elderly patients. However, because older individuals are more likely to have reduced hepatic and renal function, concurrent illnesses, and polypharmacy, closer monitoring – particularly of liver enzymes – may be prudent. Your doctor will determine the most appropriate monitoring schedule based on your individual health status, comorbidities, and other medications.
Patients with Renal or Hepatic Impairment
Renal and Hepatic Impairment
Riluzol PMCS is contraindicated in patients with liver disease or elevated baseline transaminases (more than 3 times the upper limit of normal). In mild to moderate renal impairment, no dose adjustment has been formally established; however, no studies have been performed in patients with severe renal insufficiency (creatinine clearance below 30 mL/min), and caution is advised. Close monitoring of liver function and general clinical status is recommended in these patient groups.
Missed Dose
If you forget to take a dose of Riluzol PMCS, skip the missed dose and take the next dose at your regular scheduled time. Do not take a double dose to compensate for the forgotten tablet. Taking two doses too close together can increase the risk of side effects, particularly nausea and elevated liver enzymes. If you frequently forget doses, consider setting a daily alarm, using a pill organizer, or linking doses to regular daily activities (such as brushing your teeth in the morning and evening). If you miss doses for several days in a row, contact your doctor for advice.
Overdose
If you or someone else has taken more Riluzol PMCS tablets than prescribed, contact your doctor or go to the nearest emergency department immediately. Symptoms of overdose may include severe nausea, vomiting, drowsiness, confusion, seizures, methemoglobinemia (a rare blood disorder), and potentially serious liver damage. There is no specific antidote for riluzole overdose; treatment is supportive and symptomatic, including activated charcoal if the overdose is recent. Bring the medication packaging with you to help healthcare providers understand what has been taken and in what quantity.
| Patient Group | Dose | Frequency | Notes |
|---|---|---|---|
| Adults | 50 mg | Twice daily (every 12 hours) | Total daily dose: 100 mg |
| Elderly (65+ years) | 50 mg | Twice daily (every 12 hours) | No dose adjustment; monitor liver function closely |
| Children (<18 years) | Not recommended | N/A | Insufficient safety and efficacy data |
| Mild-Moderate Renal Impairment | 50 mg | Twice daily | Use with caution; monitor closely |
| Severe Renal Impairment | Not studied | N/A | Avoid unless benefit outweighs risk |
| Hepatic Impairment | Contraindicated | N/A | Do not use in liver disease or elevated ALT/AST >3x ULN |
What Are the Side Effects of Riluzol PMCS?
The most common side effects of Riluzol PMCS include tiredness (asthenia), nausea, and elevated liver enzymes. More serious but less common side effects include hepatitis (liver inflammation), neutropenia (low white blood cells), and interstitial lung disease. Report any unexplained fever, jaundice, or breathing difficulties to your doctor immediately.
Like all medicines, Riluzol PMCS can cause side effects, although not everybody experiences them. Most side effects are mild to moderate and may improve as your body adjusts to the medication. However, some side effects can be serious and require immediate medical attention. Understanding what to watch for can help you work with your doctor to manage your treatment safely. Because Riluzol PMCS contains the same active ingredient as other riluzole products, the side effect profile is identical to that of the reference product.
- Fever of unknown origin: Riluzole can lower your white blood cell count (neutropenia). Your doctor may need to check your blood to rule out neutropenia, which increases infection risk
- Yellowing of the skin or eyes (jaundice), whole-body itching, persistent nausea, or vomiting: These may be signs of liver damage (hepatitis). Regular blood tests are essential to detect this early
- Dry cough or shortness of breath: These may indicate interstitial lung disease, a rare but potentially serious complication. A chest X-ray and lung function tests may be needed
- Severe allergic reaction: Swelling of the face, lips, or throat, severe skin rash, difficulty breathing – seek emergency medical help
Very Common Side Effects
- Tiredness (asthenia/fatigue)
- Nausea
- Elevated blood levels of liver enzymes (transaminases, ALT/AST)
Common Side Effects
- Dizziness
- Drowsiness (somnolence)
- Headache
- Tingling in or around the mouth (oral paraesthesia)
- Increased heart rate (tachycardia)
- Abdominal pain
- Vomiting
- Diarrhea
- General pain
Uncommon Side Effects
- Anemia (low red blood cell count)
- Allergic reactions (hypersensitivity)
- Pancreatitis (inflammation of the pancreas)
Rare Side Effects
- Skin rash
- Hepatitis (liver inflammation)
- Interstitial lung disease
- Neutropenia (low white blood cell count)
- Severe allergic reactions (anaphylaxis, angioedema)
Understanding Liver-Related Side Effects
Elevated transaminases (liver enzymes ALT and AST) are among the most common side effects of riluzole and can occur in more than 10% of patients taking Riluzol PMCS. In most cases, these elevations are mild, asymptomatic, and detected only through routine blood testing. They often resolve spontaneously or after dose reduction. However, in some patients, the elevation can become clinically significant and indicate actual liver damage (hepatotoxicity).
The recommended monitoring schedule – monthly for the first three months, then every three months during the remainder of the first year, and periodically thereafter – is specifically designed to detect liver problems early, before they become clinically significant. If your ALT levels rise above 5 times the upper limit of normal, your doctor will typically discontinue Riluzol PMCS. Patients with pre-existing liver conditions, chronic alcohol consumption, or those taking other hepatotoxic medications are at higher risk and should be monitored more frequently.
Managing Common Side Effects
Nausea is one of the most frequently reported side effects and is usually mild. Taking Riluzol PMCS with food may help reduce nausea, although this is not strictly required. If nausea is persistent and bothersome, your doctor may recommend anti-nausea medication such as ondansetron or metoclopramide. Eating small, frequent meals and avoiding spicy or fatty foods may also help. Fatigue is another very common effect and can sometimes be difficult to distinguish from the fatigue caused by ALS itself. Maintaining a regular sleep schedule, pacing activities, and gentle physical activity as tolerated may help manage this symptom.
Dizziness and drowsiness can affect your ability to drive or operate machinery safely. These effects are usually transient, occurring most commonly during the first few weeks of treatment, and often improve with continued use. If they persist or interfere with daily function, discuss this with your doctor. Oral paraesthesia (tingling or numbness around the mouth) is a distinctive side effect of riluzole and is generally harmless and temporary, though it may be uncomfortable. It typically resolves without intervention.
When to Seek Emergency Care
Although most side effects are manageable, some warrant urgent medical attention. Seek emergency care if you experience: severe abdominal pain with vomiting (possible pancreatitis), sudden onset of shortness of breath or chest pain, signs of severe allergic reaction (facial swelling, difficulty breathing, widespread hives), confusion or loss of consciousness, or severe bleeding or bruising. Always bring your medication list to emergency visits.
If you experience any side effects – whether listed here or not – talk to your doctor, pharmacist, or nurse. You can also report side effects directly to your national medicines agency (for example, the FDA MedWatch program in the United States, the Yellow Card Scheme in the United Kingdom, the EMA in Europe, or equivalent national pharmacovigilance systems). By reporting side effects, you help provide important safety information about medicines and contribute to the ongoing monitoring of Riluzol PMCS and other generic products.
How Should You Store Riluzol PMCS?
Store Riluzol PMCS at room temperature (below 30°C), in the original packaging to protect from light and moisture, out of the reach and sight of children. Do not use after the expiry date printed on the packaging. Do not dispose of medicines via wastewater or household waste – return unused tablets to your pharmacy.
Proper storage of medications is important to ensure they remain effective and safe to use throughout their shelf life. Riluzol PMCS does not require refrigeration – it should be kept at normal room temperature, away from excessive heat, direct sunlight, and humid environments (such as bathrooms). Keep the tablets in their original blister packaging and carton until you are ready to take them, as the packaging provides protection against light and moisture.
Always check the expiry date on the carton and blister pack before taking a tablet. The expiry date refers to the last day of the month indicated. Do not use Riluzol PMCS after this date, as the drug's potency and safety cannot be guaranteed beyond the expiration period. If you have tablets that have expired, return them to your pharmacy for proper disposal rather than keeping them for later use.
Keep this medicine out of the sight and reach of children. Although individual tablets are unlikely to cause severe harm in small children, accidental ingestion of larger quantities can be dangerous. If a child accidentally ingests Riluzol PMCS tablets, seek medical attention immediately or call your national poison control center. Unused or expired medicines should not be thrown in regular household waste or flushed down the toilet. Instead, return them to your pharmacy for safe disposal through designated take-back programs. These measures help protect the environment from pharmaceutical contamination of water systems and soil.
Travel and Storage Tips
When traveling, keep Riluzol PMCS in your carry-on luggage rather than checked baggage to avoid extreme temperature fluctuations in cargo holds. If you travel across time zones, gradually adjust your dosing times to maintain approximately 12-hour intervals between doses. For long trips, ensure you have a sufficient supply and carry a copy of your prescription in case of lost or damaged medication. Avoid leaving the medication in hot cars or in direct sunlight, as this can degrade the active ingredient.
What Does Riluzol PMCS Contain?
Each Riluzol PMCS tablet contains 50 mg of the active substance riluzole. The tablet also contains pharmaceutical excipients (inactive ingredients) that give the tablet its physical properties. These typically include fillers, binders, disintegrants, lubricants, and film-coating agents. Always check the specific patient leaflet for the complete list of excipients in your formulation.
Understanding the composition of your medicine is important, particularly if you have known allergies or sensitivities to specific excipients. The active ingredient, riluzole, is a benzothiazole compound with the chemical name 2-amino-6-(trifluoromethoxy)benzothiazole. Each film-coated tablet contains exactly 50 mg of riluzole, which is the therapeutically active substance responsible for the drug's effect on glutamate release.
Active Ingredient
Riluzole 50 mg – a glutamate release inhibitor with neuroprotective properties. Riluzole has a molecular formula of C₈H₅F₃N₂OS and a molecular weight of approximately 234.2 g/mol. It is practically insoluble in water but soluble in dimethylformamide, dimethyl sulfoxide, and methanol. The compound appears as a white or almost white crystalline powder.
Inactive Ingredients (Excipients)
The inactive ingredients in generic riluzole formulations such as Riluzol PMCS typically serve the following pharmaceutical functions:
- Tablet core:
- Filler/diluent (commonly calcium hydrogen phosphate anhydrous or lactose monohydrate) – provides tablet bulk
- Binder (microcrystalline cellulose) – holds the tablet together
- Glidant (anhydrous colloidal silica) – improves powder flow during manufacturing
- Lubricant (magnesium stearate) – prevents sticking during compression
- Disintegrant (croscarmellose sodium or similar) – helps the tablet break apart in the stomach
- Film coating:
- Hypromellose – film-forming agent
- Macrogol (polyethylene glycol) – plasticizer
- Titanium dioxide (E171) – opacifier/whitening agent
For the exact list of excipients in your Riluzol PMCS tablets, refer to the patient information leaflet supplied with your medication or consult your pharmacist. If you have known allergies to any of these excipients, discuss alternative formulations with your healthcare provider.
Appearance and Packaging
Generic riluzole 50 mg tablets are typically film-coated and white or almost white. The exact shape, size, and any markings depend on the specific manufacturer. Riluzol PMCS is supplied in blister packs; standard pack sizes are commonly 30, 56, or 100 tablets. Check the outer carton for the exact pack size and any identifying features of your tablets.
Riluzol PMCS tablets contain less than 1 mmol (23 mg) of sodium per tablet, which means they are essentially "sodium-free." This is relevant for patients on sodium-restricted diets, such as those with heart failure, hypertension, or advanced kidney disease.
Some generic formulations of riluzole contain lactose as an excipient. If you have been told by your doctor that you have an intolerance to some sugars (such as lactose intolerance or galactose intolerance), check the patient information leaflet or consult your pharmacist before taking Riluzol PMCS.
Frequently Asked Questions About Riluzol PMCS
Riluzol PMCS is a generic medicine containing riluzole 50 mg. It is used to treat amyotrophic lateral sclerosis (ALS), also known as motor neuron disease or Lou Gehrig's disease. Riluzole works by reducing the release of glutamate, an excitatory chemical messenger in the brain that can damage nerve cells when present in excess. Riluzol PMCS has been shown to extend survival by approximately 2–3 months and may delay the need for mechanical ventilation. It does not cure ALS but helps slow disease progression as part of a comprehensive treatment plan.
Riluzol PMCS is a generic version of the reference medicine Rilutek. Both products contain the same active ingredient (riluzole), the same strength (50 mg), and the same dosage form (film-coated tablets). Generic medicines must demonstrate bioequivalence to the reference product, meaning they deliver the active ingredient into the bloodstream at a comparable rate and extent. This ensures that Riluzol PMCS has the same clinical efficacy and safety profile as Rilutek. Differences are typically limited to inactive ingredients (excipients), tablet appearance, packaging, and cost – generics are usually less expensive.
Riluzole works primarily by inhibiting the release of glutamate from presynaptic nerve terminals in the central nervous system. In ALS, motor neurons are damaged partly due to excessive glutamate activity (a process called excitotoxicity). By reducing glutamate release and blocking voltage-dependent sodium channels, riluzole helps protect remaining motor neurons from further damage. It also interferes with intracellular signaling pathways that contribute to neuronal death. Although the exact mechanism of benefit in ALS is not fully understood, these neuroprotective effects are thought to explain the modest but meaningful survival extension seen in clinical trials.
Regular blood tests are necessary because riluzole can affect your liver function. Elevated liver enzymes (transaminases) are one of the most common side effects, occurring in more than 10% of patients. Your doctor will check your liver enzymes before starting treatment, monthly for the first 3 months, every 3 months during the rest of the first year, and periodically thereafter. Additionally, riluzole can rarely lower your white blood cell count (neutropenia), so blood tests help detect this early. If significant liver enzyme elevations (more than 5 times the upper limit of normal) are detected, your doctor may need to stop the medication to prevent serious liver damage.
While there is no absolute prohibition against alcohol use with riluzole, it is generally advisable to limit or avoid alcohol consumption. Both riluzole and alcohol are metabolized by the liver, and combining them may increase the risk of hepatotoxicity (liver damage). Alcohol can also worsen common side effects such as dizziness, drowsiness, and nausea. Chronic heavy drinking substantially increases the risk of liver enzyme elevations and serious hepatotoxicity. Discuss your alcohol consumption with your doctor, who can provide personalized advice based on your liver function test results and overall health.
No, Riluzol PMCS cannot cure ALS. Currently, there is no cure for amyotrophic lateral sclerosis. Riluzole is a disease-modifying treatment that has been shown to slow disease progression and extend survival by approximately 2–3 months on average. The benefit appears greatest when treatment is started early in the disease course. Riluzole is most effective as part of a comprehensive management approach that includes physical therapy, occupational therapy, speech and swallowing therapy, nutritional support, respiratory care, and multidisciplinary team care. Ongoing research continues to explore additional treatments and combination approaches for ALS.
Difficulty swallowing (dysphagia) is a common symptom of ALS that can make taking tablets challenging. If you have trouble swallowing Riluzol PMCS tablets, talk to your doctor or pharmacist. In some countries, an oral suspension formulation of riluzole is available, which may be easier to swallow. An oral film formulation (dispersible on the tongue) is also available in some markets. Your healthcare team can advise on the best option for you, including whether tablets can be taken with thickened fluids or other swallowing aids. Never crush, chew, or alter your medication without consulting your healthcare team first, as this can affect how the drug is absorbed.
Yes, switching between the reference product Rilutek and a generic such as Riluzol PMCS is generally considered safe, as generics must demonstrate bioequivalence. Many healthcare systems encourage the use of generic medicines to reduce costs without compromising treatment. However, always discuss any planned switch with your doctor or pharmacist, especially if you have had a stable response on one formulation. If you notice any change in side effects or effectiveness after switching, inform your healthcare provider. Some patients with sensitivity to specific excipients may tolerate one formulation better than another.
References
- Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. New England Journal of Medicine. 1994;330(9):585-591. doi:10.1056/NEJM199403033300901
- Lacomblez L, Bensimon G, Leigh PN, et al. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. The Lancet. 1996;347(9013):1425-1431. doi:10.1016/S0140-6736(96)91680-3
- Miller RG, Mitchell JD, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database of Systematic Reviews. 2012;(3):CD001447. doi:10.1002/14651858.CD001447.pub3
- European Medicines Agency (EMA). Rilutek (riluzole) – Summary of Product Characteristics. Last updated 2023.
- U.S. Food and Drug Administration (FDA). Rilutek (riluzole) – Prescribing Information. Revised 2023.
- National Institute for Health and Care Excellence (NICE). Motor neurone disease: assessment and management. NICE guideline [NG42]. Updated 2024.
- Andersen PM, Abrahams S, Borasio GD, et al. EFNS guidelines on the clinical management of amyotrophic lateral sclerosis (MALS). European Journal of Neurology. 2012;19(3):360-375. doi:10.1111/j.1468-1331.2011.03501.x
- World Health Organization (WHO). WHO Model List of Essential Medicines – 23rd List, 2023.
- Bellingham MC. A review of the neural mechanisms of action and clinical efficiency of riluzole in treating amyotrophic lateral sclerosis. CNS Neuroscience & Therapeutics. 2011;17(1):4-31. doi:10.1111/j.1755-5949.2009.00116.x
- Andrews JA, Jackson CE, Heiman-Patterson TD, et al. Real-world evidence of riluzole effectiveness in treating amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration. 2020;21(7-8):509-518. doi:10.1080/21678421.2020.1771734
- European Medicines Agency (EMA). Guideline on the Investigation of Bioequivalence. CPMP/EWP/QWP/1401/98 Rev. 1.
- British National Formulary (BNF). Riluzole monograph. Joint Formulary Committee. Updated 2024.
Editorial Team
Medical Content
iMedic Medical Editorial Team
Specialists in neurology and clinical pharmacology with extensive experience in neurodegenerative disease management and generic drug information.
Medical Review
iMedic Medical Review Board
Independent panel of medical experts who review all content according to international guidelines (EMA, FDA, NICE, AAN) and the GRADE evidence framework.
This article was written based on official prescribing information from the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA), supplemented by peer-reviewed clinical trial data and international treatment guidelines. Information regarding generic equivalence follows EMA and FDA bioequivalence standards. All content is reviewed regularly to reflect the latest clinical evidence and regulatory updates.
Last medical review: | Next scheduled review: